Nov 14 (Reuters) - Corbus Pharmaceuticals Holdings Inc
said its lead drug outperformed a placebo in a
mid-stage study involving patients with a form of systemic
sclerosis, an incurable autoimmune condition caused by abnormal
growth of connective tissue.
Read more
No comments:
Post a Comment